[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2888850B1 - Nouveaux anticorps anti-igf-ir et leurs applications - Google Patents

Nouveaux anticorps anti-igf-ir et leurs applications

Info

Publication number
FR2888850B1
FR2888850B1 FR0507829A FR0507829A FR2888850B1 FR 2888850 B1 FR2888850 B1 FR 2888850B1 FR 0507829 A FR0507829 A FR 0507829A FR 0507829 A FR0507829 A FR 0507829A FR 2888850 B1 FR2888850 B1 FR 2888850B1
Authority
FR
France
Prior art keywords
igf
antibodies
applications
novel anti
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0507829A
Other languages
English (en)
Other versions
FR2888850A1 (fr
Inventor
Liliane Goetsch
Nathalie Corvaia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0507829A priority Critical patent/FR2888850B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to TW095126695A priority patent/TWI414532B/zh
Priority to CA2616099A priority patent/CA2616099C/fr
Priority to EP11161901A priority patent/EP2380913A1/fr
Priority to GT200600324A priority patent/GT200600324A/es
Priority to JP2008521987A priority patent/JP5185817B2/ja
Priority to NZ565248A priority patent/NZ565248A/en
Priority to MX2008000964A priority patent/MX2008000964A/es
Priority to PCT/EP2006/064543 priority patent/WO2007012614A2/fr
Priority to RU2008106751/10A priority patent/RU2434882C2/ru
Priority to BRPI0613642-7A priority patent/BRPI0613642A2/pt
Priority to CN200680026553.8A priority patent/CN101238149B/zh
Priority to KR1020087001940A priority patent/KR101343928B1/ko
Priority to AU2006274086A priority patent/AU2006274086B2/en
Priority to ARP060103165A priority patent/AR054175A1/es
Priority to US11/989,204 priority patent/US8361461B2/en
Priority to EP06792546.1A priority patent/EP1907426B1/fr
Publication of FR2888850A1 publication Critical patent/FR2888850A1/fr
Priority to IL188712A priority patent/IL188712A/en
Priority to ZA200800636A priority patent/ZA200800636B/xx
Priority to NO20080892A priority patent/NO20080892L/no
Priority to HK08110945.7A priority patent/HK1116201A1/xx
Publication of FR2888850B1 publication Critical patent/FR2888850B1/fr
Application granted granted Critical
Priority to US13/745,142 priority patent/US8945871B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0507829A 2005-07-22 2005-07-22 Nouveaux anticorps anti-igf-ir et leurs applications Expired - Fee Related FR2888850B1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR0507829A FR2888850B1 (fr) 2005-07-22 2005-07-22 Nouveaux anticorps anti-igf-ir et leurs applications
ARP060103165A AR054175A1 (es) 2005-07-22 2006-07-21 Nuevos anticuerpos anti-igf-ir y usos de los mismos
CA2616099A CA2616099C (fr) 2005-07-22 2006-07-21 Nouveaux anticorps anti igf-ir et leur utilisation
US11/989,204 US8361461B2 (en) 2005-07-22 2006-07-21 Anti-IGF-IR antibodies and uses thereof
JP2008521987A JP5185817B2 (ja) 2005-07-22 2006-07-21 新規の抗ｉｇｆ−ｉｒ抗体及びその使用
NZ565248A NZ565248A (en) 2005-07-22 2006-07-21 Novel anti-IGF-IR antibodies and uses thereof
MX2008000964A MX2008000964A (es) 2005-07-22 2006-07-21 Anticuerpos anti-receptor de factor de crecimiento similar a la insulina-i novedosos y usos de los mismos.
PCT/EP2006/064543 WO2007012614A2 (fr) 2005-07-22 2006-07-21 Nouveaux anticorps anti igf-ir et leur utilisation
RU2008106751/10A RU2434882C2 (ru) 2005-07-22 2006-07-21 Новые антитела к igf-ir и их применение
BRPI0613642-7A BRPI0613642A2 (pt) 2005-07-22 2006-07-21 anticorpo, hibridoma murino, ácido nucleico isolado, vetor, célula hospedeira, animal transgênico, processo para a produção de um enticorpo ou um de seus fragmentos funcionais, composição, uso de um anticorpo ou um de seus fragmentos funcionais, métodos de diagnóstico para prognosticar um potencial oncogênico de uma amostra de células da próstata, e para dar seguimento ao processo de um regime terapêutico projetado para aliviar um distúrbio patológico, kit ou conjunto para a realização de um método de diagnóstico de doença, e, métodos para modular e diminuir a atividade de igf-ir em células de mamìferos responsivas ao igf-ir, para identificar um modulador de igf-ir, para detectar um parceiro de ligação para o anticorpo, e para purificar um igf-ir a partir de uma amostra
CN200680026553.8A CN101238149B (zh) 2005-07-22 2006-07-21 新抗igf-ir抗体及其用途
KR1020087001940A KR101343928B1 (ko) 2005-07-22 2006-07-21 신규한 항－ｉｇｆ－ｉｒ 항체 및 이의 용도
TW095126695A TWI414532B (zh) 2005-07-22 2006-07-21 抗第１型類胰島素生長因子接受器之抗體及其之使用
EP11161901A EP2380913A1 (fr) 2005-07-22 2006-07-21 Nouveaux anticorps anti-IGF-IR et leurs utilisations
GT200600324A GT200600324A (es) 2005-07-22 2006-07-21 Nuevos anticuerpos anti-igf-ir y usos de los mismos
EP06792546.1A EP1907426B1 (fr) 2005-07-22 2006-07-21 Nouveaux anticorps anti igf-ir et leur utilisation
AU2006274086A AU2006274086B2 (en) 2005-07-22 2006-07-21 Novel anti-IGF-IR antibodies and uses thereof
IL188712A IL188712A (en) 2005-07-22 2008-01-10 Ir-igf antibodies and their uses
ZA200800636A ZA200800636B (en) 2005-07-22 2008-01-22 Novel anti-IGF-IR antibodies and uses thereof
NO20080892A NO20080892L (no) 2005-07-22 2008-02-20 Nye anti-IGF-IR antistoffer og anvendelse derav
HK08110945.7A HK1116201A1 (en) 2005-07-22 2008-09-30 Novel anti-igf-ir antibodies and uses thereof igf-ir
US13/745,142 US8945871B2 (en) 2005-07-22 2013-01-18 Anti-IGF-IR antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507829A FR2888850B1 (fr) 2005-07-22 2005-07-22 Nouveaux anticorps anti-igf-ir et leurs applications

Publications (2)

Publication Number Publication Date
FR2888850A1 FR2888850A1 (fr) 2007-01-26
FR2888850B1 true FR2888850B1 (fr) 2013-01-11

Family

ID=36118266

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0507829A Expired - Fee Related FR2888850B1 (fr) 2005-07-22 2005-07-22 Nouveaux anticorps anti-igf-ir et leurs applications

Country Status (20)

Country Link
US (2) US8361461B2 (fr)
EP (2) EP2380913A1 (fr)
JP (1) JP5185817B2 (fr)
KR (1) KR101343928B1 (fr)
CN (1) CN101238149B (fr)
AR (1) AR054175A1 (fr)
AU (1) AU2006274086B2 (fr)
BR (1) BRPI0613642A2 (fr)
CA (1) CA2616099C (fr)
FR (1) FR2888850B1 (fr)
GT (1) GT200600324A (fr)
HK (1) HK1116201A1 (fr)
IL (1) IL188712A (fr)
MX (1) MX2008000964A (fr)
NO (1) NO20080892L (fr)
NZ (1) NZ565248A (fr)
RU (1) RU2434882C2 (fr)
TW (1) TWI414532B (fr)
WO (1) WO2007012614A2 (fr)
ZA (1) ZA200800636B (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
WO2005016970A2 (fr) 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
KR101246504B1 (ko) 2005-06-17 2013-03-26 임클론 엘엘씨 항－ＰＤＧＦＲα 항체
CA2641310C (fr) 2006-02-03 2013-08-20 Imclone Systems Incorporated Antagonistes d'igf-ir en tant qu'adjuvants au traitement du cancer de la prostate
US7612178B2 (en) 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EA200900991A1 (ru) * 2007-02-14 2010-02-26 Глаксо Груп Лимитед Новые антитела против igf-1r
JP5240701B2 (ja) * 2007-04-19 2013-07-17 学校法人中部大学 発癌予知マーカー及びその用途
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009017679A2 (fr) * 2007-07-31 2009-02-05 Merck & Co., Inc. Anticorps spécifiques de igf-1r utiles dans la détection et le diagnostic de troubles de prolifération cellulaire
CN101842116A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 结合igf-1r多个表位的组合物
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
EP3381445B1 (fr) 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
AU2009324296B2 (en) 2008-12-12 2016-07-28 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
CA2749339A1 (fr) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Compositions d'anticorps modifiees et leurs procedes de production et d'utilisation
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2490957B1 (fr) 2009-10-23 2016-11-23 Amgen, Inc Adaptateur de fiole et système
US8444982B2 (en) * 2009-12-04 2013-05-21 The University Of Hong Kong Anti-IGF-IR antibodies and uses thereof
CA2789154C (fr) 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Souris a chaine legere commune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011150133A2 (fr) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
PL2575935T5 (pl) 2010-06-07 2023-12-11 Amgen Inc. Urządzenie do podawania leku
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
WO2012135315A1 (fr) 2011-03-31 2012-10-04 Amgen Inc. Adaptateur de flacon et système
JP6038884B2 (ja) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド 自動式注射装置
EP2734546A1 (fr) * 2011-07-18 2014-05-28 Amgen Inc. Protéines de liaison à antigène de l'apéline et leurs utilisations
DK3865581T3 (da) 2011-08-05 2024-10-21 Regeneron Pharma Humaniserede, universelle letkædemus
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA2851521C (fr) 2011-10-14 2020-09-22 Amgen Inc. Injecteur et procede d'assemblage
ES2723827T3 (es) 2011-11-11 2019-09-02 Univ Duke Terapia de combinación de fármacos para el tratamiento de tumores sólidos
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
JP5905781B2 (ja) * 2012-06-13 2016-04-20 学校法人沖縄科学技術大学院大学学園 相互作用予測装置、相互作用予測方法、および、プログラム
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
EP2879709B1 (fr) * 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation de la réponse immunitaire
ES2951440T3 (es) 2012-11-21 2023-10-20 Amgen Inc Dispositivo de administración de fármacos
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CA2904725C (fr) 2013-03-15 2022-04-12 Amgen Inc. Cartouche a medicament, auto-injecteur et systeme d'auto-injection
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
WO2014143770A1 (fr) 2013-03-15 2014-09-18 Amgen Inc. Dispositif autoinjecteur pouvant s'adapter aux contours du corps
EP3831427A1 (fr) 2013-03-22 2021-06-09 Amgen Inc. Injecteur et procédé d'assemblage
KR101627920B1 (ko) * 2013-07-16 2016-06-07 서울대학교산학협력단 인슐린 유사 성장 인자 2를 활용한 새로운 폐기종 유발 동물 모델 구축
JP7086520B2 (ja) 2013-10-24 2022-06-20 アムジエン・インコーポレーテツド インジェクター及び組み立ての方法
JP7051293B2 (ja) 2013-10-24 2022-04-11 アムジエン・インコーポレーテツド 温度感知制御を伴う薬剤送達システム
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
EP3572424B1 (fr) 2014-03-20 2022-04-20 Bristol-Myers Squibb Company Domaines de liaison à l'albumine sérique de la fibronectine de type iii
CA2942697A1 (fr) 2014-03-21 2015-09-24 Lynn Macdonald Animaux non humains qui produisent des proteines de liaison monodomaine
KR102357032B1 (ko) * 2014-04-25 2022-02-08 피에르 파브르 메디카먼트 Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
WO2015187799A1 (fr) 2014-06-03 2015-12-10 Amgen Inc. Systèmes et procédés pour traiter à distance des données collectées par un dispositif d'administration de médicament
WO2016054555A2 (fr) * 2014-10-03 2016-04-07 Novartis Ag Polythérapies
WO2016061220A2 (fr) 2014-10-14 2016-04-21 Amgen Inc. Dispositif d'injection de médicament comportant des témoins visuels et sonores
EP3689394A1 (fr) 2014-12-19 2020-08-05 Amgen Inc. Dispositif d'administration de médicaments avec bouton mobile ou panneau d'interface utilisateur
WO2016100781A1 (fr) 2014-12-19 2016-06-23 Amgen Inc. Dispositif d'administration de médicament doté d'un capteur de proximité
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
EP3261690B1 (fr) 2015-02-27 2021-12-15 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
CA2979702A1 (fr) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Animaux non humains qui selectionnent des regions variables de chaines legeres qui se lient a l'antigene
MX2018001182A (es) 2015-07-28 2018-04-20 Univ Pennsylvania Monocitos/macrofagos modificados que expresan receptores de antigeno quimerico y sus usos.
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
JP6893504B2 (ja) 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン
JP6968790B2 (ja) * 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ発現癌の処置のための組成物
WO2017100501A1 (fr) 2015-12-09 2017-06-15 Amgen Inc. Auto-injecteur avec capuchon de signalisation
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (fr) 2016-05-02 2017-11-09 Amgen Inc. Adaptateur de seringue et guide pour remplir un injecteur sur le corps
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (fr) 2016-05-16 2017-11-23 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
EP3465124A1 (fr) 2016-06-03 2019-04-10 Amgen Inc. Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (fr) 2016-10-25 2019-09-04 Amgen Inc. Injecteur porté sur le corps
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
EP3582825A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
CA3052204A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Mecanisme d'insertion pour dispositif d'administration de medicament
CA3050927A1 (fr) 2017-03-06 2018-09-13 Brian Stonecipher Dispositif d'administration de medicaments dote d'une fonction de prevention d'activation
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
US11986624B2 (en) 2017-03-09 2024-05-21 Amgen Inc. Insertion mechanism for drug delivery device
FI3600491T3 (fi) 2017-03-28 2023-10-20 Amgen Inc Männänvarren ja ruiskukokoonpanon järjestelmä ja menetelmä
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
WO2019018169A1 (fr) 2017-07-21 2019-01-24 Amgen Inc. Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022950A1 (fr) 2017-07-25 2019-01-31 Amgen Inc. Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP4085942A1 (fr) 2017-07-25 2022-11-09 Amgen Inc. Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US20210332141A1 (en) 2017-08-30 2021-10-28 Amgen Inc. Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use
EP3691717B1 (fr) 2017-10-04 2023-02-08 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
EP3691716B1 (fr) 2017-10-06 2023-11-29 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3694578A1 (fr) 2017-10-09 2020-08-19 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
MA50527A (fr) 2017-11-03 2020-09-09 Amgen Inc Système et approches pour stériliser un dispositif d'administration de médicament
EP3707075A1 (fr) 2017-11-06 2020-09-16 Amgen Inc. Ensembles de remplissage-finition et procédés associés
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
CA3079540A1 (fr) 2017-11-16 2019-05-23 Amgen Inc. Mecanisme d'insertion d'aiguille pour dispositif d'administration de medicament
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
BR112020011810A2 (pt) * 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
EP3826699A1 (fr) 2018-07-24 2021-06-02 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
CA3103681A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de medicaments
WO2020023220A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
EP3829692A1 (fr) 2018-07-31 2021-06-09 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de médicament
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
CA3110371A1 (fr) 2018-09-28 2020-04-02 Amgen Inc. Ensemble d'activation d'echappement de fil de muscle pour un dispositif d'administration de medicament
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
AU2019355979A1 (en) 2018-10-05 2021-03-18 Amgen Inc. Drug delivery device having dose indicator
AU2019359801A1 (en) 2018-10-15 2021-03-18 Amgen Inc. Platform assembly process for drug delivery device
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091981A1 (fr) 2018-11-01 2020-05-07 Amgen Inc. Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
AR117673A1 (es) * 2018-12-03 2021-08-25 Teijin Pharma Ltd Anticuerpo humanizado anti-receptor de igf-i
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR20230042691A (ko) 2020-06-04 2023-03-29 카리스마 테라퓨틱스 인코포레이티드 키메라 항원 수용체에 대한 신규한 작제물
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
AU2023212834A1 (en) * 2022-01-29 2024-09-12 Minghui Pharmaceutical (Hangzhou) Limited Antigen-binding protein and use thereof
WO2024208244A1 (fr) * 2023-04-04 2024-10-10 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anticorps anti-igf1r et leurs utilisations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AU2002231368C1 (en) * 2001-01-05 2018-08-16 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
ES2283759T3 (es) * 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
EP1506286B1 (fr) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Anticorps anti-igfr humain neutralisant
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP1613658B1 (fr) * 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
WO2005016970A2 (fr) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
CA2532966C (fr) 2003-07-15 2012-12-04 Chugai Seiyaku Kabushiki Kaisha Production d'igm par des cellules transformees et methodes de quantification de cette production
CN1835975B (zh) 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2005058967A2 (fr) * 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations

Also Published As

Publication number Publication date
TW200740846A (en) 2007-11-01
US8361461B2 (en) 2013-01-29
US8945871B2 (en) 2015-02-03
RU2434882C2 (ru) 2011-11-27
EP1907426B1 (fr) 2013-08-21
US20130125252A1 (en) 2013-05-16
MX2008000964A (es) 2008-03-27
IL188712A (en) 2014-05-28
GT200600324A (es) 2007-02-14
JP2009502129A (ja) 2009-01-29
NZ565248A (en) 2011-11-25
ZA200800636B (en) 2008-12-31
KR20080032117A (ko) 2008-04-14
KR101343928B1 (ko) 2013-12-31
HK1116201A1 (en) 2008-12-19
RU2008106751A (ru) 2009-08-27
EP2380913A1 (fr) 2011-10-26
NO20080892L (no) 2008-04-16
IL188712A0 (en) 2008-08-07
AR054175A1 (es) 2007-06-06
CN101238149A (zh) 2008-08-06
AU2006274086A1 (en) 2007-02-01
EP1907426A2 (fr) 2008-04-09
TWI414532B (zh) 2013-11-11
BRPI0613642A2 (pt) 2012-11-06
CN101238149B (zh) 2014-07-23
US20090265797A1 (en) 2009-10-22
CA2616099A1 (fr) 2007-02-01
WO2007012614A3 (fr) 2007-03-29
WO2007012614A2 (fr) 2007-02-01
JP5185817B2 (ja) 2013-04-17
FR2888850A1 (fr) 2007-01-26
CA2616099C (fr) 2018-04-24
AU2006274086B2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
FR2888850B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
CY2016030I1 (el) Αντισωματα εναντι της il-17
DE602005015349D1 (de) Verbesserte kautschukmodifizierte monovinyliden-aromapolymere und daraus hergestellte erzeugnisse
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
CY2017006I2 (el) Αερολυμενες φθοροκινολονες και χρησεις αυτων
CY2015030I1 (el) Ανταγωνιστικα αντισωματα il-17
DK2032606T3 (da) Antistoffer og immunkonjugater og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2993187T3 (da) Antistoffer rettet mod her-3 og anvendelser deraf
NO20082454L (no) Anti-alfa2 integrin antistoffer og deres anvendelser
ATE523524T1 (de) Antikörper und immunkonjugate gegen tat226
DK1866339T3 (da) GTR-bindende molekyler og anvendelser heraf
DK1871423T3 (da) Konjugat af nanopartikler og aktive stof
DK1896073T3 (da) Anti-il-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK1883665T3 (da) Polylactidsammensætninger og anvendelser deraf
NO20071430L (no) Anti-OX4OL antistoffer
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
FR2909092B1 (fr) Nouveaux anticorps anti-proliferation
DE602005007987D1 (de) achtelung und -entschachtelung
DK1814977T3 (da) Arthrospira-baserede sammensætninger og anvendelser deraf
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
FR2907786B1 (fr) Thionucleosides et applications pharmaceutiques
DE112004002526D2 (de) Kompakte Differentialanordnung

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160331